A Phase 1/2 Single-Center Trial Combining Venetoclax With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (CLAG-M) for Patients With AML and High-Grade Myeloid Neoplasms
This study is testing a new combination of a targeted medicine called venetoclax and standard chemotherapy drugs to treat fast-growing blood cancers like acute myeloid leukemia. Researchers want to find the best and safest doses of these medications working together to destroy cancer cells more effectively.
You may be able to join if you have been diagnosed with acute myeloid leukemia or a related high-risk blood cancer that is newly diagnosed, has returned, or has not responded to previous treatments. Certain health conditions, such as untreated infections or cancer that has spread to the brain, mean you cannot participate.
Participants will receive a combination of venetoclax and several chemotherapy medications, along with supportive drugs to help the body make white blood cells. You will also have regular medical tests, including blood draws and bone marrow checks, to see how well the treatment is working.
This study is currently recruiting patients and takes place in Seattle, Washington, United States. Your care team will give you all the specific details about the schedule and clinic visits.
- 1Tests a combination of venetoclax and chemotherapy for blood cancers
- 2Aims to find the safest and most effective doses for patients
- 3Currently recruiting participants in Seattle, Washington
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.